Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000255817 | SCV000322431 | pathogenic | not provided | 2016-04-27 | criteria provided, single submitter | clinical testing | The R137X pathogenic variant in the HEXA gene has been reported previously in association with Tay Sachs disease (Akli et al., 1991; Mules et al., 1992). This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The R137X variant was not observed in approximately 6500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. We interpret R137X as a pathogenic variant. |
Eurofins Ntd Llc |
RCV000255817 | SCV000331825 | pathogenic | not provided | 2015-11-06 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000004110 | SCV000893377 | pathogenic | Tay-Sachs disease | 2022-02-16 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000004110 | SCV000917518 | pathogenic | Tay-Sachs disease | 2018-07-23 | criteria provided, single submitter | clinical testing | Variant summary: HEXA c.409C>T (p.Arg137X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 2.9e-05 in 277008 control chromosomes. c.409C>T has been reported in the literature in individuals affected with Tay-Sachs Disease (Gort_2012, Mules_1992, Ozkara_1998, Zampieri_2012). These data indicate that the variant is associated with disease. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Invitae | RCV000004110 | SCV001209223 | pathogenic | Tay-Sachs disease | 2023-12-23 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg137*) in the HEXA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in HEXA are known to be pathogenic (PMID: 1833974, 8490625). This variant is present in population databases (rs121907962, gnomAD 0.006%). This premature translational stop signal has been observed in individual(s) with hexosaminidase A deficiency (PMID: 1837283, 18648917, 22441121, 22789865). ClinVar contains an entry for this variant (Variation ID: 3904). For these reasons, this variant has been classified as Pathogenic. |
DASA | RCV000004110 | SCV002061148 | pathogenic | Tay-Sachs disease | 2022-01-05 | criteria provided, single submitter | clinical testing | The c.409C>T;p.(Arg137*) variant creates a premature translational stop signal in the the HEXA gene. It is expected to result in an absent or disrupted protein product -PVS1. This sequence change has been observed in affected individual(s) and ClinVar contains an entry for this variant (Clinvar ID: 3904; PMID: 1532289; 1837283; 9851891; 14685153; 18648917; 22441121; 22789865) - PS4. The variant is present at low allele frequencies population databases (rs121907962– gnomAD 0,00329%; ABraOM 0.000854 frequency - http://abraom.ib.usp.br/) - PM2_supporting. The p.(Arg137*) was detected in trans with a pathogenic variant (PMID: 1837283; 1864891; 9851891; 22441121; 22789865) - PM3_strong. In summary, the currently available evidence indicates that the variant is pathogenic. |
OMIM | RCV000004110 | SCV000024276 | affects | Tay-Sachs disease | 1992-04-01 | no assertion criteria provided | literature only | |
Natera, |
RCV000004110 | SCV002089751 | pathogenic | Tay-Sachs disease | 2017-03-17 | no assertion criteria provided | clinical testing |